CAR T therapy holds unprecedented promise not just for the treatment but also the irreversible curing of cancer; however, barriers include complex procedures, high cost of implementation and manufacturing, and the application to solid tumours. In vivo cell and gene engineering holds tremendous promise as the future direction for CAR Therapy. The generation of chimeric antigen receptor (CAR) T cells in vivo can be achieved by delivering mRNA in T cell-targeted lipid nanoparticles (LNPs) and in vivo programming. This exciting area will be featured at in the Innovative CAR T Therapy conference at PEGS Europe and will review innovative CAR structures, gene-editing tools, and gene delivery techniques to help design and develop new CAR constructs and engineer therapies in vivo. Various approaches and technologies will be assessed for their immunogenicity, potency, and modes of CAR delivery, both permanent and transient. This conference will examine what it will take to transform new CAR constructs and in vivo CAR therapy from proof-of-concept to a robust technology for clinical use.
Scientific Advisory Board:
Melita Irving, PhD, Group Leader, Ludwig Institute for Cancer Research, University of Lausanne
Astero Klampatsa, PhD, Team Leader, Cancer Therapeutics, Institute of Cancer Research